Presentation of latest clinical data: Invitation to the scientific symposium

During the 19th Bremer Symposium of Intensive Care latest clinical user data of the iLA Membrane Ventilator® will be presented. These data enable new therapy chances for acute and chronic pulmonary patients.

From 18th till 20th February 2009 the 19th Symposium of Intensive Care will take place in Bremen, Germany. We would like to turn your special attention to the symposium “Perspectives beyond protective ventilation” which will take place on Friday, 20th February 2009. As a press representative you are cordially invited to attend this symposium:

Invitation to the symposium „Perspectives beyond protective ventilation“:

Where: Fair and Congress Centre Bürgerweide, Bremen, Germany
Room Scharoun
When: Friday, 20th February 2009
9.00 am – 10.30 am

As mechanical ventilation is directly associated with a high mortality rate on the intensive care unit, the understanding of lung protecting ventilation, so called “protective” ventilation, has been broadly established in the intensive care medicine. But this can be exceeded! Innovative therapies such as the iLA Membrane Ventilator® or high frequency oscillatory ventilation allow a real lung protection which can go beyond current “protective” ventilation standards. Thus new therapy chances will be provided – for example for patients with an acute respiratory failure, an acute aggravation of a chronic pulmonary disease (so called exacerbated COPD) or for patients being in a prolonged weaning process from the mechanical ventilation.

New findings can increase survival rates
Through this symposium the participants will be informed on newest experiences in the application of these latest technologies. On the basis of actual clinical data and case studies the enabling therapy methods will be presented. Physician and nurses will learn about new therapy approaches which focus on healing and regeneration of the lung and therefore might improve patient’s outcome.

Worldwide reputable speakers
You can look forward to a very interesting morning with worldwide known speakers:
• Prof. Kuhlen (HELIOS Hospital Berlin-Buch, Germany) will present latest clinical user data of the iLA Membrane Ventilator® and
• Prof. Bein (University Hospital Regensburg, Germany) questions in his speech if a tidal volume of 6 ml/kg PBW is protective enough.
• Mrs. Dr. Rosseau (Charité Berlin, Germany) will discuss case studies regarding the therapeutically option for the iLA Membrane Ventilator® on hypercapnia insufficiency and
• Prof. Quintel (University Hospital Göttingen, Germany) will present the high frequency oscillatory ventilation as a further option for protective ventilation.

Early get up pays off!
For that you can attend this interesting symposium invigorated, we offer you at our booth B6 a delicious hangover breakfast at 8 am on Friday morning.

We are looking forward to your visit and the discussion with you during the intensive care congress in Bremen.

You can download high-resolution pictures as well as the literature compendium on www.novalung.com or it will be sent on request via email.

Please send us a copy of your imprint.

Background information Novalung GmbH - Driver of a paradigm shift

Novalung is the only company worldwide producing an artificial lung assist device – “Made in Germany” - which breathes outside the patient. The iLA Membrane Ventilator® eliminates the carbon dioxide outside the human lung driven by the human heart like a natural organ. Thereby the patient’s lung is protected as it doesn’t need to perform the complete gas exchange.

The iLA Membrane Ventilator® is implemented without surgery in a groin artery and vein by using two specifically developed NovaPort® vascular accesses. The artificial lung measures 14x14 cm only. Inside a hollow fibre membrane takes over the function of the pulmonary alveoli and completes the else wise common mechanical ventilation or can even replace it sometimes. Protective ventilation strategies can now be persecuted consequently; the natural lunge gets „time to heal“®. The iLA Membrane Ventilator® has been approved for a temporary use up to 29 days for patients of intensive care units.

In 2007 Novalung increased its portfolio by a high frequency oscillatory ventilator, Vision α®, being a quantum leap in mechanical ventilation. The high frequency oscillator focus on a very
protective and efficient oxygenation and enables therefore an optimal combination with the Membrane Ventilator® therapy.

Contact:

Franziska Preissing
Head of Marketing
franziska.preissing@novalung.com
Novalung GmbH
Egerten 3
D-74388 Talheim
Tel.: +49 7133 90 11 130
Fax: +49 7133 90 11 230
www.novalung.com

This release was published on openPR.